Sunshine Heart (NASDAQ:SSH) shares have taken a beating since their fall 2013 peak, falling about 60% from their peak on a combination of slow pivotal trial enrollment and a sharp turn away from risky, speculative health care stocks. With Sunshine Heart due to report results tomorrow (May 13), it is a safe bet that investors will be keenly focused on the enrollment figures for the COUNTER-HF study, even though it may be too optimistic to assume that the company's awareness efforts have had a major impact at this point.
A Common Problem, But One Without Easy Solutions
Sunshine Heart has definitely had some challenges getting patients enrolled in its COUNTER-HF study; the study that the company needs to...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|